Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.47 |
| ▸ | POLG | P54098 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21636984 | 0.91 | ADK (0.44) | P2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL22524066 | 0.87 | ADK (0.43) | — | |
| SCHEMBL29487848 | 0.84 | POLB (0.58) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL26031206 | 0.84 | POLB (0.58) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL889285 | 0.84 | POLB (0.58) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL23978346 | 0.84 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RX7 | |
| Dda-Triphosphate SCHEMBL79815 | 0.84 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RX7 | |
| Dda-Triphosphate SCHEMBL12932305 | 0.84 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RX7 | |
| Dda-Triphosphate SCHEMBL30301198 | 0.84 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RX7 | |
| Dda-Triphosphate SCHEMBL24767736 | 0.84 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548909-B2 | Methods of using nucleotide analogues | IsoPlexis Corporation (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022072731-A1 | RAPID AND HIGHLY SENSITIVE LUMINESCENT BIOMOLECULE DETECTION | ASCELLA BIOSYSTEMS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20210002720-A1 | DNA SEQUENCING REACTION ADDITIVE | IsoPlexis Corporation | 2021-01-07 | — | — | US | disclosed |
| US-10844430-B2 | DNA sequencing reaction additive | QIAGEN SCIENCES, LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190226018-A1 | SEQUENCING ADDITIVE | IsoPlexis Corporation | 2019-07-25 | — | — | US | disclosed |
| US-10301346-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-10273539-B2 | Methods of using nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170137878-A1 | METHODS OF USING NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-18 | — | — | US | disclosed |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548909-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | P2RX3 397/4885P2RX1 549/4885P2RX2 502/4885 |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | P2RX3 332/4885P2RX1 426/4885P2RX2 418/4885 |
| US-10844430-B2 | DNA sequencing reaction additive | RNGTT, NSUN2, NT5C3B | P2RX3 848/4885P2RX1 1518/4885P2RX2 1395/4885 |
| US-20190226018-A1 | SEQUENCING ADDITIVE | NT5C3B, RNGTT, NSUN2 | P2RX3 511/4885P2RX1 1047/4885P2RX2 808/4885 |
| US-10301346-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | P2RX3 332/4885P2RX1 426/4885P2RX2 418/4885 |
| US-20210002720-A1 | DNA SEQUENCING REACTION ADDITIVE | RNGTT, NSUN2, NT5C3B | P2RX3 848/4885P2RX1 1518/4885P2RX2 1395/4885 |
| US-10273539-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | P2RX3 397/4885P2RX1 549/4885P2RX2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.